10 Stocks Making Big M&A News and Rumors This Week

Here’s your Cheat Sheet to this week’s top mergers and acquisition news:

Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now!

Actavis (NASDAQ:ACT): Current price $127.31

On Monday, it was announced that Actavis will purchase Warner Chilcott in an all-stock transaction valued at roughly $8.5 billion. Once completed, the acquisition will form a global specialty pharmaceutical firm holding around $11 billion in combined annual revenue, and will create the number-three such company in the United States with about $3 billion in annual revenues, concentrated upon core therapeutic categories of Women’s Health, Gastroenterology, Urology, and Dermatology.  The proposed deal was unanimously approved by the boards of both Actavis  and Warner Chilcott.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ACT

Meade Instruments Corp. (NASDAQ:MEAD) Current price $3.43

Jinghua Optics & Electronics Co. said Monday that Meade and its wholly-owned subsidiary, JOC North America, and JOCNA’s wholly-owned merger subsidiary, have reached a definitive merger agreement for JOCNA to purchase all outstanding shares of Meade for around $4.5 million, or $3.45 per share. The transaction will be funded with cash and should be concluded by the end of July, subject to shareholder approval.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

MEAD

Plains Exploration & Production Co. (NYSE:PXP): Current price $48.98

The amended merger agreement between Freeport-McMoRan Copper & Gold (NYSE:FCX) and Plains Exploration & Production Co., is getting the thumbs-up from Paulson & Co., whose funds hold as of the record date 12.8 million shares or about 9.9 percent of the outstanding shares of the later. On Monday, Paulson issued a statement concerning the deal, stating in part, ”Paulson & Co. appreciates the flexibility of both Plains and Freeport in adding incremental cash to the transaction and will vote all the shares owned by funds under its management in favor of the merger.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

PXP

 Autodesk (NASDAQ:ADSK): Current price $36.08

Autodesk will acquire the browser-based 3D design tool Tinkercad, which addition will help to broaden the popular Autodesk 123D repertoire of applications, and supports Autodesk’s mission to help anyone imagine, design, and create anything. The purchase should also revive the Tinkercad service and community, in the aftermath of a previously-reported shutdown by its founders and creators.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ADSK

Don’t Miss: 6 Tech Millionaires Made By Monster Mergers.

The Blackstone Group (NYSE:BX): Current price $22.64

The specialty chemicals producer Rockwood Holdings’ pigments units have enticed offers from buyout firms that include Blackstone Group and Advent International Corp, according to some knowledgeable sources, who also said that the auction for the assets, in which Apollo Global Management, Bain Capital, Golden Gate Capital and Rhone Group are also involved, is presently in its second round, with meetings with management going forward.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BX

Warner Chilcott (NASDAQ:WCRX): Current price $19.96

The analyst Aaron Gal at Bernstein wrote in a note Tuesday morning suggesting that Warner Chilcott’s “willingness” for an all-share transaction might provoke other suitors to have a go at a possible bid. Gal also cited benefits from tax synergies, and that Mylan could potentially offer Warner Chilcott $22 per share. At the present time, the Actavis (NYSE:ACT) offer is at $20.08 per share.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

WCRX

BlackRock (NYSE:BLK): Current price $283.21

The asset manager will acquire the private-equity property investment advisory firm MGPA at an unreported price, so as to expand its real-estate business in the Asia-Pacific region and in Europe. Currently, MGPA manages roughly $12 billion, concentrating upon real estate funds management, co-investments, and separate-account mandates for institutional investors, according to a Tuesday BlackRock statement. The transaction should close in the third quarter and is not expected to materially affect BlackRock’s earnings per share, according to the company.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BLK

SoundBite Communications (NASDAQ:SDBT): Current price $4.95

On Tuesday, Genesys said that it will acquire SoundBite at a price of $5 per share, with an aggregate value of around $100.4 million. SoundBite provides cloud-based proactive collections, payments, and mobile marketing applications, alongside proactive customer service solutions to enterprises. The transaction will be accomplished via a cash tender offer to be followed by a second step merger. The closing of the transaction should take place early in the third quarter. Genesys is  a provider of customer engagement and contact center solutions.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

SDBT

Investing Insights: Will Corning Continue to Make New 52-Week Highs?

Elan Corporation (NYSE:ELN): Current price $12.47

On Thursday, Elan announced that its board as decided that the privately-held investment firm Royalty Pharma’s revised offer as of May 20, to purchase all of Elan’s shares at $12.50 through its shell subsidiary Echo Pharma Acquisition Limited, substantially undervalues the firm. Elan Chairman Robert A. Ingram commented that “the revised offer from Royalty Pharma continues to grossly undervalue our company’s current business platform and our future prospects. This offer is no more than an opportunistic attempt to acquire our company at a substantial discount at our Shareholders’ expense. Put simply, for Royalty Pharma to win, you our Shareholders must lose. Accordingly, the Board unanimously and without reservation rejects the revised Royalty Pharma offer.”

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ELN

BioTime (NYSE:BTX): Current price $4.37

BioTime said on Thursday that at a special meeting held on Tuesday, its shareholders approved the proposals connected with the planned purchase of stem cell-related assets from Geron Corporation (NASDAQ:GERN) by its subsidiary Asterias Biotherapeutics. Each of the proposals received a minimum of 32,459,164 votes in favor from the 34,450,307 shares that were represented and voted, in person or by proxy, at the meeting. More information in regards to the proposals approved at the meeting and the vote totals can be found in a Form 8-K that BioTime has filed with the U.S. Securities and Exchange Commission.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

BTX

Fidelity National Financial (NYSE:FNF): Current price $26.17

Title insurer Fidelity National and the buyout firm Thomas H. Lee Partners are reportedly in advanced discussions to acquire Lender Processing Services (NYSE:LPS) for roughly $2.9 billion, say persons familiar with the matter. The purchase would bring Lender Processing Services back in the fold of Fidelity National Financial, which was once its parent. Through the terms being discussed, the buyers would fund the transaction with a mixture of cash and Fidelity National Financial stock, and the acquisition would value Lender Processing Services shares by about $33, according to some of the sources.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

FNF

Don’t Miss: Can Ford Stay Steady in Canada?

More Articles About:    

More from The Cheat Sheet